Skip to main content
Dwight Koeberl, MD, Medical Genetics, Durham, NC, Duke University Hospital

DwightKoeberlMD

Medical Genetics Durham, NC

Clinical Biochemical Genetics, Clinical Genetics, Pediatric Medical Genetics

Associate Professor/Clinical Genetics

Dr. Koeberl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Koeberl's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Medical Genetics and Genomics, 1993 - 1996
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Pediatrics, 1990 - 1992
  • Mayo Graduate School
    Mayo Graduate SchoolPh.D., Biochemistry, 1990
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 1990
  • Carleton College
    Carleton CollegeB.A., Chemistry, Magna Cum Laude, 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - Present
  • NC State Medical License
    NC State Medical License 1999 - 2025
  • American Board of Medical Genetics and Genomics Clinical Biochemical Genetics
  • American Board of Pediatrics Pediatrics
  • American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Awards, Honors, & Recognition

  • America's Best Doctors 2009
  • Judith Graham Pool Fellowship National Hemophilia Society, University of Washington, 1993
  • March of Dimes Predoctoral Fellowship 1986
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine pompe disease  
    Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, and Kishnani PS, Mol Genet Metab, 1/1/2012
  • Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease  
    Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, Kemper AR, Clay TM, Koeberl DD, Hum Gene Ther, 1/1/2012
  • Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus- mediated gene therapy  
    Sun,B, Young SP, Li P, Di C, Brown T, Salva MZ, Li S, Bird A, Yan Z, Auten R, Hauschka SD, and Koeberl DD, Mol Ther, 1/1/2008
  • Join now to see all

Press Mentions

  • AskBio Gets $235 Million in Gene Therapy Support
    AskBio Gets $235 Million in Gene Therapy SupportApril 12th, 2019
  • AskBio Partners with TPG and Vida Ventures
    AskBio Partners with TPG and Vida VenturesApril 11th, 2019
  • AskBio Reels in $235M to Ramp up Gene Therapy Clinical Trials, Manufacturing
    AskBio Reels in $235M to Ramp up Gene Therapy Clinical Trials, ManufacturingApril 11th, 2019
  • Join now to see all

Grant Support

  • Phase 1/2 Study of clenbuterol for the treatment of Pompe diseaseFood and Drug Administration2013–Present
  • Clinical Trial Planning in Pompe DiseaseNational Institutes of Health2013–2014
  • Enhanced muscle-targeted gene therapy for Pompe diseaseMuscular Dystrophy Association2012–2014
  • Mechanisms For Immune Tolerance In Pompe DiseaseEunice Kennedy Shriver National Institute Of Child Health &Human Development2009–2010
  • Gene Delivery To Striated Muscle By Systemic AAV VectorsNational Heart, Lung, And Blood Institute2006–2010

Professional Memberships

Hospital Affiliations